

Mark C. McKenna

Chairman & CEO, Mirador Therapeutics, Inc

Mark C. McKenna is the founder, Chairman, and CEO of Mirador Therapeutics, and a renowned biotech entrepreneur, executive, and director known for his exceptional leadership and visionary approach. Mirador is a next-generation precision medicine company focused on developing first-in-class or best-in-class precision medicines for immunology and inflammation. Launched in 2024, Mirador has raised over \$650 million plus from leading life sciences investors and is based in San Diego, CA. Prior to Mirador, Mr. McKenna served as Chairman, President, and CEO of Prometheus Biosciences from 2019 until its acquisition by Merck for \$10.8 billion in June 2023. Under his leadership, Prometheus raised over \$1 billion in private and public financing, was recognized as the top-performing biotech IPO of 2021, and pioneered the first precision therapeutics clinical trial for immune-mediated diseases. This led to its acquisition by Merck, resulting in the largest buyout of company with a pre-Phase 3 asset to date. Prior to Prometheus Mr. McKenna was the President of Salix Pharmaceuticals and a corporate officer at Bausch + Lomb. There, he revitalized the gastroenterology business through strategic acquisitions and product launches, doubling revenue to over \$2 billion and significantly enhancing operating margins. He also spent over a decade at Bausch + Lomb, where he was SVP and General Manager of the US Vision Care business. Mr. McKenna began his career at Johnson & Johnson, where he held several positions of increasing responsibility. He currently serves as the Chairman of Apogee Therapeutics, Inc. (Nasdaq: APGE) and is a board member of Spyre Therapeutics, Inc. (Nasdaq: SYRE) and New Amsterdam Pharma (Nasdaq: NAMS). In addition, Mr. McKenna is a Venture Partner at Arch and Senior Advisor to Fairmount Funds. Mr. McKenna holds a B.S. in marketing from Arizona State University and an MBA from Azusa Pacific University. Mr. McKenna also completed the Wharton's Fellows Program at the University of Pennsylvania School of Business. Mr. McKenna is passionate about solving big problems in medicine and is regularly featured on CNBC's Mad Money and Bloomberg radio. In addition, Mr. McKenna is a frequent speaker at the Longwood Healthcare Conference and other industry thought leader events. In 2023 he was selected as EY's Entrepreneur of the year, being recognized for his contributions to advancement of entrepreneurship and science.